Look back at pharma news in week to Mar 16

18 March 2018

By Barbara Obstoj-Cardwell. Editor

New research results from Regeneron Pharmaceuticals and partner Sanofi on their PCSK9 drug Praluent and a novel scheme to improve access to the expensive drug attracted a great deal of attention last week, as did late-stage trial results with AbbVie’s elagolix for uterine fibroids. In deal-making news, there was Biogen picking up Pfizer’s neurological cast-off PF-04958242, and Lundbeck acquiring Prexton Therapeutics along with its Parkinson’s disease drug foliglurax, as well as Ionis Pharmaceuticals upping its stake in Akcea Therapeutics and off-loading its rare disease drug candidate inotersen.

Praluent’s Odyssey ends with a whimper

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK